These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29050697)

  • 1. How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?
    Chen X; Wood BL
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):237-248. PubMed ID: 29050697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
    Chen X; Wood BL
    Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
    Nunes V; Cazzaniga G; Biondi A
    Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
    Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
    Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
    Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.
    Ceppi F; Rizzati F; Colombini A; Conter V; Cazzaniga G
    Expert Rev Hematol; 2021 Sep; 14(9):795-807. PubMed ID: 34374613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
    Campana D
    Curr Opin Hematol; 2012 Jul; 19(4):313-8. PubMed ID: 22525580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I investigate minimal residual disease in acute lymphoblastic leukemia.
    Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
    Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
    Short NJ; Jabbour E
    Curr Oncol Rep; 2017 Jan; 19(1):6. PubMed ID: 28205134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
    Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS; Hsiao CC; Sheen JM; Cheng CN
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey.
    Tüfekçi Ö; Evim MS; Güneş AM; Celkan T; Karapinar DY; Kaya Z; Baysal B; Baytan B; Koçak Ü; Yilmaz Ş; Çinar S; Ören H
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e396-e402. PubMed ID: 35129146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia.
    Qin X; Zhang MY; Liu WJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6885-6895. PubMed ID: 30402854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.
    Tran V; Salafian K; Michaels K; Jones C; Reed D; Keng M; El Chaer F
    Curr Hematol Malig Rep; 2024 Aug; 19(4):186-196. PubMed ID: 38888822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.